Search
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalIt is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies.
Favipiravir
go.drugbank.com/drugs/DB12466ApprovedInvestigational[A191721,L12090] Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19.[A191724,A191958,A191961]
Dicyclomine
go.drugbank.com/drugs/DB00804ApprovedInvestigationalDicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder
Bentiromide
go.drugbank.com/drugs/DB00522ApprovedWithdrawnBentiromide is a dipeptide that is used in the bentiromide test, which is a screening test for evaluating pancreatic exocrine function and monitoring the adequacy of supplemental pancreatic therapy. It is typically administered orally. C...
Saxagliptin
go.drugbank.com/drugs/DB06335ApprovedInvestigationalSaxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Safinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalSafinamide is for the treatment of parkinson's disease. It was approved in Europe in February 2015, and in the United States on March 21, 2017.
CHGN111
go.drugbank.com/drugs/DB06376ExperimentalNumerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative
C11-12 isoparaffin
go.drugbank.com/drugs/DB11329ApprovedIt is found in cosmetic and personal care products as solvents or skin conditioning agent.
Pyrvinium
go.drugbank.com/drugs/DB06816ApprovedInvestigationalWithdrawnSeveral forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and pamoate. Pyrvinum's anti-cancer properties are currently under investigation.
Dutasteride
go.drugbank.com/drugs/DB01126ApprovedInvestigationalDutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to
Products: DUTASTERIDE DOC GENERICI